Ionis Pharmaceuticals, Inc. IONS
40.42 USD -0.82 (-1.99%)
At closeNov 3, 2026, 5:04 PM EST
41.21 +0.79 +1.95%
After hours · Nov 3, 5:04 PM ET
40.26 Day range 41.83
40.26 52-week range 86.74
- YTD
- -48.91%
- 1 year
- -45.12%
Analyst view
Consensus: buy
Buy
Price target (mean) 84.13 +108.1% upside
Now 40.42
- Target (low)
- 58.00
- Target (mean)
- 84.13
- Target (high)
- 105.00
Ratings (0m) 25 21 buy · 4 hold · 0 sell
- Strong buy9
- Buy12
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 25
- 1 month ago 24
- 2 months ago 24
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.93444 | -1.08 – -0.65 | -0.6125 | -52.6% | 184.38M | +17.4% | 9 |
| Next quarter | -0.8875 | -1.20 – -0.61 | -1.15 | +22.7% | 236.90M | +16.7% | 8 |
| Current year | -2.62 | -2.99 – -2.12 | -1.54 | -70.0% | 922.37M | -2.3% | 10 |
| Next year | -1.15 | -2.47 – 0.60 | -2.62 | +56.3% | 1.36B | +47.4% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | BMO Capital | Upgrade | Market Perform | Outperform |
| Oct 15, 2026 | UBS | Upgrade | Neutral | Buy |
| Sep 24, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 22, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 15, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 9, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 8, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 8, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Sep 8, 2026 | BMO Capital | Maintained | Market Perform | Market Perform |
| Sep 8, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 4, 2026 | Needham | Reiterated | Buy | Buy |
| Sep 4, 2026 | BMO Capital | Maintained | Market Perform | Market Perform |
| Sep 4, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 31, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 19, 2026 | BMO Capital | Initiated | Outperform | Market Perform |
| Aug 3, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 30, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 16, 2026 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Jul 13, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 10, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 10, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 10, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 10, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 10, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 9, 2026 | Jefferies | Maintained | Buy | Buy |
| Jul 9, 2026 | Needham | Maintained | Buy | Buy |
| Jun 25, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |